Maia Biotechnology Inc (MAIA) is a clinical-stage biopharmaceutical company developing telomere-targeting cancer therapies. The company generates no product revenue, funding operations through equity issuances and private placements rather than commercial sales. Its lead program, ateganosine (THIO), is a first-in-class telomere-targeting agent licensed from The University of Texas Southwestern Medical Center under a patent and technology license agreement dated December 23, 2020. As of the 10-K filed March 23, 2026, ateganosine is in a Phase 3 pivotal trial (THIO-104) evaluating its efficacy sequenced with a checkpoint inhibitor as third-line treatment for advanced non-small cell lung cancer, with the first patient dosed on December 11, 2025. The trial targets enrollment of up to 300 patients across sites in Taiwan, Turkey, select European Medicines Agency countries, and Georgia. MAIA has no approved products and no commercial revenue as of the fiscal year ended covered by this filing.

Revenue model

No product revenue. Operations are funded through equity offerings and private placements. In December 2025, the company raised approximately $1.51 million in gross proceeds through a non-brokered private placement of common stock and warrants at $1.224 per share to accredited investors and company directors.

Products and services

Ateganosine (THIO), a telomere-targeting compound licensed from the University of Texas Southwestern Medical Center, is the sole disclosed clinical-stage product candidate. It is being studied as a third-line treatment for advanced non-small cell lung cancer in the THIO-104 Phase 3 trial.

Customers and end markets

End market is oncology, specifically advanced non-small cell lung cancer patients who have progressed on prior therapies. No commercial customers exist as of the filing date.

Value-chain role

Clinical-stage drug developer. MAIA in-licenses intellectual property from academic institutions, sponsors clinical trials, and relies on contract manufacturers subject to FDA current good manufacturing practice regulations. The company holds no manufacturing facilities.

Geographic exposure

Clinical trial sites active or approved in Taiwan, Turkey, select European Medicines Agency member countries, and Georgia as of December 2025.

Source: SEC 10-K, filed 2026-03-23

Industry: Pharmaceutical Preparations Peers: ABVC Biopharma Inc Spyre Therapeutics Inc Ainos Inc Neurogene Inc Aravive, Inc. Avalo Therapeutics Inc Codiak BioSciences, Inc. Comera Life Sciences Holdings, Inc. Marker Therapeutics Inc